Developer docs
API playgroundTry for free, no card

Search company profiles

Anteris Technologies

Full company profile

uuid000316h

Namestring
Anteris Technologies
Legal namestring
Anteris Technologies Global Corp.
Websiteurl
anteristech.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Anteris Technologies is a structural heart medical device company developing the DurAVR Transcatheter Heart Valve (THV) System for the treatment of severe calcific aortic stenosis. The system is built around three integrated components: the DurAVR THV itself — a first-in-class, single-piece, native-shaped biomimetic valve designed to mimic healthy aortic valve performance and restore laminar blood flow; the proprietary ADAPT anti-calcification bovine tissue that has been clinically proven calcium-free for up to 10 years and used in 55,000+ patients as a cardiac/vascular patch; and the ComASUR balloon-expandable delivery system featuring commissure alignment technology and an expandable 14Fr sheath. Headline clinical outcomes include an Effective Orifice Area of ~2.1–2.2 cm², mean pressure gradients of ~8–9 mmHg, and 97–98.5% freedom from moderate or greater prosthesis-patient mismatch in matched analyses against Edwards Sapien 3.

The company is pre-revenue and currently monetizes nothing commercially; near-term economic value derives from clinical evidence generation and eventual regulatory approvals rather than device sales. Its go-to-market motion is executing the global pivotal PARADIGM trial — a randomized, head-to-head study of approximately 1,000 patients across ~85 sites in the U.S., Europe, and Canada — to support FDA and EMA submissions, with first patients treated at Copenhagen University Hospital (Oct 2025) and Montefiore Medical Center (May 2026), and French ANSM clearance secured in June 2026. Future commercial distribution is planned via direct hospital sales to cardiac centers and structural heart programs in the U.S. and Europe, with Medtronic positioned as a potential co-commercialization and manufacturing partner following its $90M strategic investment in January 2026.

Anteris is dual-listed on NASDAQ and ASX (ticker: AVR), having completed its U.S. IPO in December 2024 and a $320M aggregate capital raise in January 2026. Headcount is 101–250 with offices in Toowong/Brisbane (Australia), Geneva (Switzerland), Eagan and Brooklyn Park (Minnesota, U.S.), and Perth (Australia); a new 181,436 sq ft manufacturing facility in Brooklyn Park begins September 2026. The wholly-owned v2vmedtech subsidiary (VClip mitral/tricuspid repair program) is in transition after Anteris terminated its development agreement in April 2026 with a $400K break fee.

Short descriptiontext

Anteris Technologies is a pre-revenue structural heart medical device company developing the DurAVR biomimetic transcatheter heart valve system, built on its proprietary ADAPT anti-calcification tissue, for patients with severe calcific aortic stenosis, currently advancing the global pivotal PARADIGM trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEagan, United States
HQ citystring
Eagan
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter heart valves, structural heart devices, aortic stenosis treatment, anti-calcification tissue, cardiac valve replacement
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Scientific Research and Development Services5417
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Structural Heart Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1DurAVR THV System (future)
TypeHardware Sales
Description

Pre-revenue company; no commercial products yet. Planning to commercialize the DurAVR Transcatheter Heart Valve System following successful completion of PARADIGM pivotal trial and regulatory approvals from FDA and EMA. Revenue expected from device sales to hospitals and cardiac centers.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1DurAVR
Description

First-in-class biomimetic transcatheter aortic heart valve designed to mimic healthy aortic valve performance

anteristech.com
+2 more records
Core offering1 text field

Anteris Technologies develops and intends to commercialize the DurAVR® Transcatheter Heart Valve System, an integrated TAVR platform comprising a first-in-class biomimetic single-piece valve made from proprietary ADAPT® anti-calcification bovine tissue and delivered via the ComASUR® balloon-expandable delivery system. The company is pre-commercial and currently generating pivotal clinical evidence through the global PARADIGM trial (approximately 1,000 patients across US, Europe, and Canada) to support FDA and EMA regulatory approvals for the treatment of severe calcific aortic stenosis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Effective Orifice Area (EOA) of 2.1-2.2 cm2 sustained to 1 year, significantly larger than typical TAVR devices
+6 more records
Product overview1 text field

Anteris Technologies is a structural heart company that has developed a unified product platform centered around the DurAVR® Transcatheter Heart Valve System. The system comprises three integrated components: the DurAVR® THV (a biomimetic transcatheter heart valve made from single-piece ADAPT® anti-calcification tissue), the ADAPT® Tissue (proprietary bovine tissue proven calcium-free for up to 10 years), and the ComASUR® Delivery System (balloon-expandable delivery platform with commissure alignment). The company is conducting the PARADIGM global pivotal trial to support regulatory approvals in the US, Europe, and Canada.

Product and service1 record
1DurAVR® Transcatheter Heart Valve (THV)
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1v2vmedtech, inc.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Anteris terminated its development agreement with v2vmedtech, inc. (a related party through shared leadership including CEO Wayne Paterson as Chair and CFO Matthew McDonnell as CFO). The agreement originally dated April 18, 2023 was in Stage 2 of development. Termination required a $400,000 break fee payment. v2vmedtech's initial shareholders retain the right to either acquire Anteris's equity interest in full or reduce it to a capped minority ownership percentage.

investing.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Edwards Lifesciences is the global market leader in TAVR with the Sapien platform (Sapien 3, Sapien X4) — directly comparable to Anteris as the benchmark comparator in the PARADIGM trial. Matched analyses have shown DurAVR achieving superior hemodynamics versus Edwards Sapien 3.

TypeDirect peer
Description

Medtronic's Evolut TAVR platform is the second major incumbent in the structural heart market and the strategic investor behind Anteris's $90M placement. It is the direct competitive counterpart in aortic valve replacement and a likely co-commercialization partner.

TypeDirect peer
Description

Boston Scientific markets the Acurate neo2 TAVR valve in Europe and is expanding in structural heart. It is a direct peer competing for hospital cardiac center contracts and physician adoption in the same TAVR procedure category.

4Abbott
TypeBroad incumbent
Description

Abbott offers the Portico and Navitor TAVR platforms within a broader structural heart and cardiovascular portfolio. While not focused exclusively on TAVR like Anteris, it competes in the same hospital purchasing decisions and procedure volumes.

TypeEmerging player
Description

JenaValve is a privately-held TAVR developer with FDA breakthrough designation for its Trilogy device targeting aortic regurgitation and severe aortic stenosis. It is an emerging direct competitor pursuing similar differentiated indications and clinical trial pathways.

6Venus Medtech
TypeEmerging player
Description

Venus Medtech (Hangzhou) is a Chinese structural heart company developing TAVR and mitral/tricuspid technologies for global markets. It is an emerging peer pursuing similar biomimetic and durability-focused design philosophies for transcatheter valve replacement.

TypeEmerging player
Description

4C Medical is an early-stage structural heart company developing the AltaValve system for mitral regurgitation. While focused on mitral rather than aortic, it represents the same next-generation biomimetic/transcatheter approach within structural heart.

TypeEmerging player
Description

NeoChord (co-founded by Anteris Chairman John Seaberg) develops transcatheter mitral chordal repair technology. It is an adjacent structural heart peer addressing the same patient demographic of younger, lower-risk valvular disease patients via minimally invasive approaches.

TypeEmerging player
Description

Cardiovalve (acquired by Venus Medtech) developed a transcatheter mitral and tricuspid valve replacement system. It is an emerging peer in the structural heart space targeting similar patient segments and procedural innovations as Anteris.

TypeRegional player
Description

Peijia Medical is a Chinese structural heart company developing TAVR (Taurus) and transcatheter mitral/tricuspid repair devices primarily for the Asia-Pacific market. It is a regional peer with comparable technology focus but limited direct overlap with Anteris's US/European commercial focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anteris Technologies

Structural Heart Devicesanteristech.com

Anteris Technologies is a pre-revenue structural heart medical device company developing the DurAVR biomimetic transcatheter heart valve system, built on its proprietary ADAPT anti-calcification tissue, for patients with severe calcific aortic stenosis, currently advancing the global pivotal PARADIGM trial.

What Anteris Technologies does

Anteris Technologies is a structural heart medical device company developing the DurAVR Transcatheter Heart Valve (THV) System for the treatment of severe calcific aortic stenosis. The system is built around three integrated components: the DurAVR THV itself — a first-in-class, single-piece, native-shaped biomimetic valve designed to mimic healthy aortic valve performance and restore laminar blood flow; the proprietary ADAPT anti-calcification bovine tissue that has been clinically proven calcium-free for up to 10 years and used in 55,000+ patients as a cardiac/vascular patch; and the ComASUR balloon-expandable delivery system featuring commissure alignment technology and an expandable 14Fr sheath. Headline clinical outcomes include an Effective Orifice Area of ~2.1–2.2 cm², mean pressure gradients of ~8–9 mmHg, and 97–98.5% freedom from moderate or greater prosthesis-patient mismatch in matched analyses against Edwards Sapien 3.

The company is pre-revenue and currently monetizes nothing commercially; near-term economic value derives from clinical evidence generation and eventual regulatory approvals rather than device sales. Its go-to-market motion is executing the global pivotal PARADIGM trial — a randomized, head-to-head study of approximately 1,000 patients across ~85 sites in the U.S., Europe, and Canada — to support FDA and EMA submissions, with first patients treated at Copenhagen University Hospital (Oct 2025) and Montefiore Medical Center (May 2026), and French ANSM clearance secured in June 2026. Future commercial distribution is planned via direct hospital sales to cardiac centers and structural heart programs in the U.S. and Europe, with Medtronic positioned as a potential co-commercialization and manufacturing partner following its $90M strategic investment in January 2026.

Anteris is dual-listed on NASDAQ and ASX (ticker: AVR), having completed its U.S. IPO in December 2024 and a $320M aggregate capital raise in January 2026. Headcount is 101–250 with offices in Toowong/Brisbane (Australia), Geneva (Switzerland), Eagan and Brooklyn Park (Minnesota, U.S.), and Perth (Australia); a new 181,436 sq ft manufacturing facility in Brooklyn Park begins September 2026. The wholly-owned v2vmedtech subsidiary (VClip mitral/tricuspid repair program) is in transition after Anteris terminated its development agreement in April 2026 with a $400K break fee.

Anteris Technologies firmographics

Firmographics
Name
Anteris Technologies
Legal name
Anteris Technologies Global Corp.
Website
https://anteristech.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Anteris Technologies is a pre-revenue structural heart medical device company developing the DurAVR biomimetic transcatheter heart valve system, built on its proprietary ADAPT anti-calcification tissue, for patients with severe calcific aortic stenosis, currently advancing the global pivotal PARADIGM trial.
Ownership category
akta.pro rank

Anteris Technologies industry classification

Industry
Product category
Structural Heart Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)

Keywords

  • Transcatheter heart valves
  • Structural heart devices
  • Aortic stenosis treatment
  • Anti-calcification tissue
  • Cardiac valve replacement

Where Anteris Technologies is headquartered

Location

Headquarters

HQ city
Eagan
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Anteris Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. DurAVR THV System (future): Pre-revenue company; no commercial products yet. Planning to commercialize the DurAVR Transcatheter Heart Valve System following successful completion of PARADIGM pivotal trial and regulatory approvals from FDA and EMA. Revenue expected from device sales to hospitals and cardiac centers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Anteris Technologies product offering

Product offering

Core offering

Anteris Technologies develops and intends to commercialize the DurAVR® Transcatheter Heart Valve System, an integrated TAVR platform comprising a first-in-class biomimetic single-piece valve made from proprietary ADAPT® anti-calcification bovine tissue and delivered via the ComASUR® balloon-expandable delivery system. The company is pre-commercial and currently generating pivotal clinical evidence through the global PARADIGM trial (approximately 1,000 patients across US, Europe, and Canada) to support FDA and EMA regulatory approvals for the treatment of severe calcific aortic stenosis.

Product overview

Anteris Technologies is a structural heart company that has developed a unified product platform centered around the DurAVR® Transcatheter Heart Valve System. The system comprises three integrated components: the DurAVR® THV (a biomimetic transcatheter heart valve made from single-piece ADAPT® anti-calcification tissue), the ADAPT® Tissue (proprietary bovine tissue proven calcium-free for up to 10 years), and the ComASUR® Delivery System (balloon-expandable delivery platform with commissure alignment). The company is conducting the PARADIGM global pivotal trial to support regulatory approvals in the US, Europe, and Canada.

Differentiator

Problem solved

Functional benefit

Brands

  • DurAVR: First-in-class biomimetic transcatheter aortic heart valve designed to mimic healthy aortic valve performance
  • ADAPT
  • ComASUR

Products and services

  • DurAVR® Transcatheter Heart Valve (THV)

Quantifiable outcome

  • Effective Orifice Area (EOA) of 2.1-2.2 cm2 sustained to 1 year, significantly larger than typical TAVR devices
  • +6 more outcomes

Companies that use Anteris Technologies

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Anteris Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Anteris Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • v2vmedtech, inc.minorStrategic or Co-development Partner · 29 April 2026Anteris terminated its development agreement with v2vmedtech, inc. (a related party through shared leadership including CEO Wayne Paterson as Chair and CFO Matthew McDonnell as CFO). The agreement originally dated April 18, 2023 was in Stage 2 of development. Termination required a $400,000 break fee payment. v2vmedtech's initial shareholders retain the right to either acquire Anteris's equity interest in full or reduce it to a capped minority ownership percentage.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Anteris Technologies competitors and assessment

Company assessment

Direct peers

  • Edwards Lifesciences: Edwards Lifesciences is the global market leader in TAVR with the Sapien platform (Sapien 3, Sapien X4) — directly comparable to Anteris as the benchmark comparator in the PARADIGM trial. Matched analyses have shown DurAVR achieving superior hemodynamics versus Edwards Sapien 3.
  • Medtronic: Medtronic's Evolut TAVR platform is the second major incumbent in the structural heart market and the strategic investor behind Anteris's $90M placement. It is the direct competitive counterpart in aortic valve replacement and a likely co-commercialization partner.
  • Boston Scientific: Boston Scientific markets the Acurate neo2 TAVR valve in Europe and is expanding in structural heart. It is a direct peer competing for hospital cardiac center contracts and physician adoption in the same TAVR procedure category.

Broad incumbents

  • Abbott: Abbott offers the Portico and Navitor TAVR platforms within a broader structural heart and cardiovascular portfolio. While not focused exclusively on TAVR like Anteris, it competes in the same hospital purchasing decisions and procedure volumes.

Emerging players

  • JenaValve Technology: JenaValve is a privately-held TAVR developer with FDA breakthrough designation for its Trilogy device targeting aortic regurgitation and severe aortic stenosis. It is an emerging direct competitor pursuing similar differentiated indications and clinical trial pathways.
  • Venus Medtech: Venus Medtech (Hangzhou) is a Chinese structural heart company developing TAVR and mitral/tricuspid technologies for global markets. It is an emerging peer pursuing similar biomimetic and durability-focused design philosophies for transcatheter valve replacement.
  • 4C Medical Technologies: 4C Medical is an early-stage structural heart company developing the AltaValve system for mitral regurgitation. While focused on mitral rather than aortic, it represents the same next-generation biomimetic/transcatheter approach within structural heart.
  • NeoChord: NeoChord (co-founded by Anteris Chairman John Seaberg) develops transcatheter mitral chordal repair technology. It is an adjacent structural heart peer addressing the same patient demographic of younger, lower-risk valvular disease patients via minimally invasive approaches.
  • Cardiovalve: Cardiovalve (acquired by Venus Medtech) developed a transcatheter mitral and tricuspid valve replacement system. It is an emerging peer in the structural heart space targeting similar patient segments and procedural innovations as Anteris.

Regional players

  • Peijia Medical: Peijia Medical is a Chinese structural heart company developing TAVR (Taurus) and transcatheter mitral/tricuspid repair devices primarily for the Asia-Pacific market. It is a regional peer with comparable technology focus but limited direct overlap with Anteris's US/European commercial focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Anteris Technologies social profiles

Digital presence

Anteris Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anteris Technologies leadership team

Management profile

Number of profiles

Profiles9 records

Anteris Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Anteris Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anteris Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anteris Technologies

What does Anteris Technologies do?

Anteris Technologies develops and intends to commercialize the DurAVR® Transcatheter Heart Valve System, an integrated TAVR platform comprising a first-in-class biomimetic single-piece valve made from proprietary ADAPT® anti-calcification bovine tissue and delivered via the ComASUR® balloon-expandable delivery system. The company is pre-commercial and currently generating pivotal clinical evidence through the global PARADIGM trial (approximately 1,000 patients across US, Europe, and Canada) to support FDA and EMA regulatory approvals for the treatment of severe calcific aortic stenosis.

Is Anteris Technologies a public or private company?

Anteris Technologies is a public company. It is classified as public and is currently operating.

When was Anteris Technologies founded?

Anteris Technologies was founded in 2015. It employs 101 to 250 people.

Where is Anteris Technologies based?

Anteris Technologies is headquartered in Eagan, United States, in the North America region.

How does Anteris Technologies make money?

One revenue line is on record: durAVR THV System (future).

Who are Anteris Technologies's main competitors?

Direct peers on record are Edwards Lifesciences, Medtronic and Boston Scientific. Abbott is listed as a broad incumbent. Emerging players are JenaValve Technology, Venus Medtech, 4C Medical Technologies, NeoChord and Cardiovalve. Peijia Medical is listed as a regional player.

Does Anteris Technologies have an API?

No public API is recorded for Anteris Technologies.

What industry is Anteris Technologies in?

Anteris Technologies's product category is Structural Heart Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldAnteris Technologies Global (NASDAQ:AVR) Stock Price Target Cut by BarclaysBarclays cut its price target on Anteris Technologies Global from $10.00 to $9.00, keeping an equal-weight rating. The stock fell 7.5% to $5.42, while the company reported a quarterly loss of $0.28 per share, missing revenue estimates. Analysts average a "Hold" rating with a $13.75 target.Defense WorldNeurAxis (NASDAQ:NRXS) and Anteris Technologies Global (NASDAQ:AVR) Head-To-Head ReviewNeurAxis and Anteris Technologies Global are compared on institutional ownership, analyst ratings, and financial metrics. NeurAxis beats Anteris on 9 of 14 factors, with higher revenue and lower P/E, but Anteris has higher upside potential. NeurAxis's beta is 1.39 versus Anteris's 2.02.TradingViewBarclays maintains Anteris Technologies Glb at Equal-Weight, lowers price target to $9 from $10Barclays maintained Anteris Technologies Glb at Equal-Weight and lowered its price target to $9 from $10, a 10% decrease. The target implies an upside of 53.6% from the Nov 12 close of $5.86.Seeking AlphaAnteris Technologies Global Corp. GAAP EPS of -$0.28 beats by $0.03, revenue of $0.52M misseAnteris Technologies Global Corp. reported Q3 GAAP EPS of -$0.28, beating by $0.03, but revenue of $0.52M missed by $2.21M. Revenue grew 20.9% year-over-year.American Banking and Market NewsAnteris Technologies Global Corp. (AVR) – What Are Brokerages Thinking About This Stock?Anteris Technologies Global has a consensus 'Hold' rating from five analysts, with an average price target of $14.00. The company missed Q2 estimates with a loss of $0.30 per share and revenue of $1.01 million. Major shareholder L1 Capital bought 648,455 shares, increasing its stake by 5.35%.The future of tradingAnteris Reports No Moderate or Severe Prosthesis-Patient Mismatch at 30 Days in Medium-Size DurAVR StudyAnteris Technologies reported 30-day results for its medium-size DurAVR transcatheter heart valve in 22 severe aortic stenosis patients with medium-sized aortic annuli, presented at TCT 2026. The valve showed favorable blood-flow performance with no valve-related deaths, moderate or severe leakage, or moderate or severe prosthesis-patient mismatch. The ongoing PARADIGM pivotal trial is enrolling patients to compare DurAVR with commercially available replacement valves.TradingViewAnteris Technologies Global Corp. (AVR) Reports 30-Day DurAVR Medium-Size THV OutcomesAnteris reported 30-day outcomes for its Medium-size DurAVR THV in 22 severe aortic stenosis patients, showing single-digit mean gradients, large effective orifice areas, no moderate/severe paravalvular leak, no valve-related mortality, and 100% freedom from moderate/severe periprosthetic motion. The data expands evidence ahead of the PARADIGM pivotal RCT.YahooAnteris Technologies takes aim at the future of heart valve careAnteris Technologies is developing the DurAVR transcatheter heart valve, a biomimetic device made from bovine pericardial tissue to treat aortic stenosis. The company is evaluating it in the PARADIGM trial, which includes over 1,000 patients and compares DurAVR to commercially available TAVR devices. The trial's results will determine whether DurAVR is as safe and effective as existing alternatives.The future of tradingAnteris Gets German Regulatory Clearance for DurAVR Heart Valve TrialAnteris Technologies received German regulatory clearance for its PARADIGM pivotal trial of the DurAVR transcatheter heart valve. The clearance enables patient recruitment at German centers for the trial targeting severe calcific aortic stenosis.TradingViewAnteris Technologies Global Corp. (AVR) Wins German OK to Enroll PARADIGM TrialAnteris Technologies received full BfArM clearance to start patient recruitment in Germany for its PARADIGM trial of the DurAVR THV for severe aortic stenosis. The trial enrolls about 1,000 randomized patients with a primary endpoint of 1-year composite death, stroke, or cardiovascular hospitalization.